DR. BARRY MICHAEL SHERMAN, M.D.
Osteopathic Medicine in Burlingame, CA
License number
California C42166
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
2830 Churchill Dr., Burlingame, CA 94010
Phone
(650) 635-6053
(650) 653-6057 (Fax)
(650) 343-3636
(650) 653-6057 (Fax)
(650) 343-3636
Professional information
Treatment Of Uterine Cancer And Ovarian Cancer With A Parp Inhibitor Alone Or In Conbination With Anti-Tumor Agents
US Patent:
2010000, Jan 14, 2010
Filed:
Jul 14, 2009
Appl. No.:
12/502943
Inventors:
Barry M. Sherman - Hillsborough CA, US
Charles Bradley - Half Moon Bay CA, US
Valeria S. Ossovskaya - San Francisco CA, US
Charles Bradley - Half Moon Bay CA, US
Valeria S. Ossovskaya - San Francisco CA, US
Assignee:
BiPar Sciences, Inc. - South San Francisco CA
International Classification:
A61K 31/7068, A61K 31/4375, A61K 31/337
US Classification:
514 49, 514283, 514449
Abstract:
In one aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a subject at least one PARP inhibitor in combination with at least one anti-tumor agent.
Method Of Treating Diseases With Parp Inhibitors
US Patent:
2010027, Nov 4, 2010
Filed:
Mar 26, 2010
Appl. No.:
12/748209
Inventors:
Valeria S. OSSOVSKAYA - San Francisco CA, US
Barry M. SHERMAN - Hillsborough CA, US
Barry M. SHERMAN - Hillsborough CA, US
Assignee:
BiPar Sciences, Inc. - South San Francisco CA
International Classification:
C12Q 1/48, A61K 31/166, A61P 35/00, A61P 37/00, A61P 7/12, A61P 3/04, A61P 25/16, A61P 25/26, A61P 25/28, A61P 13/00, A61P 11/00, A61P 15/00
US Classification:
435 15, 514617, 514619, 514622
Abstract:
The present invention relates to methods of identifying a disease treatable with PARP modulators by identifying a level of PARP in a sample of a subject, making a decision regarding identifying the disease treatable by the PARP modulators wherein the decision is made based on the level of PARP. The method further comprises of treating the disease in the subject with the PARP modulators. The methods relate to identifying up-regulated PARP in a disease and making a decision regarding the treatment of the disease with PARP inhibitors. The extent of PARP up-regulation in a disease can also help in determining the efficacy of the treatment with PARP inhibitors. The present invention also relates to methods of identifying a disease treatable with PARP modulators by identifying a level of PARP in a plurality of samples from a population, making a decision regarding identifying the disease treatable by the PARP modulators wherein the decision is made based on the level of PARP. The method further comprises of treating the disease in a subject population with the PARP modulators. The methods relate to identifying up-regulated PARP in a disease and making a decision regarding the treatment of the disease with PARP inhibitors. The extent of PARP up-regulation in a disease can also help in determining the efficacy of the treatment with PARP inhibitors.The present invention discloses various diseases that have up-regulated or down-regulated PARP and can be treated with PARP inhibitors or PARP activators, respectively. The examples of the diseases include cancer, inflammation, metabolic disease, CVS disease, CNS disease, disorder of hematolymphoid system, disorder of endocrine and neuroendocrine, disorder of urinary tract, disorder of respiratory system, disorder of female reproductive system, and disorder of male reproductive system.
Drug Design For Tubulin Inhibitors, Compositions, And Methods Of Treatment Thereof
US Patent:
2009029, Nov 26, 2009
Filed:
May 21, 2009
Appl. No.:
12/454802
Inventors:
Valeria Ossovskaya - San Francisco CA, US
John Burnier - Pacifica CA, US
Barry Sherman - Hillsborough CA, US
Max Totrov - San Diego CA, US
John Burnier - Pacifica CA, US
Barry Sherman - Hillsborough CA, US
Max Totrov - San Diego CA, US
Assignee:
BiPar Sciences, Inc. - South San Francisco CA
International Classification:
A61K 31/661, G01N 33/53, G06G 7/58, A61K 31/135, A61K 31/12, A61K 31/495, C07C 213/00, C07C 45/00, A61P 35/00, A61P 5/00, A61P 11/00, A61P 13/00, A61P 15/00
US Classification:
514125, 436501, 703 12, 514646, 514683, 51425212, 564430, 568315
Abstract:
The present invention relates to a computer-assisted method of a designing of a tubulin inhibitor comprising: a) determining an interaction between a tubulin protein and a chemical known to bind the tubulin protein by evaluating a binding of the tubulin protein to the chemical known to bind the tubulin protein; b) based on the interaction, designing a candidate tubulin inhibitor; c) determining an interaction between the tubulin protein and the candidate tubulin inhibitor by evaluating a binding of the tubulin protein to the candidate tubulin inhibitor; and d) concluding that the candidate tubulin inhibitor inhibits the tubulin protein wherein the conclusion is based on the interaction of step c). The invention also provides compositions and methods of treatment of diseases with the candidate tubulin inhibitors.
Methods Of Diagnosing And Treating Parp-Mediated Diseases
US Patent:
2009027, Nov 5, 2009
Filed:
Feb 4, 2009
Appl. No.:
12/322551
Inventors:
Valeria S. Ossovskaya - San Francisco CA, US
Barry M. Sherman - Hillsborough CA, US
Barry M. Sherman - Hillsborough CA, US
Assignee:
BiPar Sciences, Inc. - Brisbane CA
International Classification:
A61K 31/47, C12Q 1/68, A61K 31/415, A61K 31/40, A61K 31/04, A61K 31/015
US Classification:
514307, 435 6, 514311, 514396, 514412, 514741, 514765
Abstract:
Disclosed are methods of identifying a disease treatable with modulators of differentially expressed genes in a disease, including at least PARP modulators, by identifying the level of expression of differentially expressed genes, including at least PARP, in a plurality of samples from a population, making a decision regarding identifying the disease treatable by modulators to the differentially expressed genes wherein the decision is made based on the level of expression of the differentially expressed genes. The method can further comprise treating the disease in a subject population with modulators of identified differentially expressed genes. The methods relate to identifying up-regulated expression of identified differentially-expressed genes in a disease and making a decision regarding the treatment of the disease. The level of expression of the differentially expressed genes in a disease can also help in determining the efficacy of the treatment with modulators to the differentially expressed genes.
Monitoring Of The Inhibition Of Fatty Acid Synthesis By Iodo-Nitrobenzamide Compounds
US Patent:
7994222, Aug 9, 2011
Filed:
Sep 5, 2007
Appl. No.:
11/850624
Inventors:
Valeria S. Ossovskaya - San Francisco CA, US
Barry M. Sherman - Hillsborough CA, US
Barry M. Sherman - Hillsborough CA, US
Assignee:
BiPar Sciences, Inc. - South San Francisco CA
International Classification:
A61K 31/165, A61P 3/04
US Classification:
514617, 514613
Abstract:
The present invention relates to a method of treating a fatty acid synthesis related disease comprising administering to a patient in need thereof an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis, wherein the fatty acid synthesis related disease is obesity, diabetes, or cardiovascular disease. The present invention also relates to a method of treating a cancer in a subject comprising: (i) identifying a level of fatty acid in a sample from the subject, and (ii) administering an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis in the subject, wherein the administration is based on the level of fatty acid, thereby treating the cancer in the subject. The present invention further relates to a method of treating Her-2 related cancers by administering to a patient in need thereof an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis.
Inhibition Of Fatty Acid Synthesis By Iodo-Nitrobenzamide Compounds And Methods Of Treatment Thereof
US Patent:
2012000, Jan 5, 2012
Filed:
Jun 27, 2011
Appl. No.:
13/169785
Inventors:
Valeria Ossovskaya - San Francisco CA, US
Barry Sherman - Hillsborough CA, US
Barry Sherman - Hillsborough CA, US
Assignee:
BiPar Sciences, Inc. - South San Francisco CA
International Classification:
A61K 31/166, A61K 31/47, A61K 31/404, A61P 35/00, A61K 31/42, A61K 31/4245, A61K 31/381, A61P 3/04, A61K 31/198, A61K 31/425
US Classification:
514307, 514619, 514562, 514618, 514415, 514359, 514364, 514438
Abstract:
The present invention relates to a method of treating a fatty acid synthesis related disease comprising administering to a patient in need thereof an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis, wherein the fatty acid synthesis related disease is obesity, diabetes, or cardiovascular disease. The present invention also relates to a method of treating a cancer in a subject comprising: (i) identifying a level of fatty acid in a sample from the subject, and (ii) administering an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis in the subject, wherein the administration is based on the level of fatty acid, thereby treating the cancer in the subject. The present invention further relates to a method of treating Her-2 related cancers by administering to a patient in need thereof an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis.
Novel Compositions And Methods For Enhancing Potency Or Reducing Adverse Side Effects Of Opioid Agonists
US Patent:
2004002, Feb 5, 2004
Filed:
Aug 26, 2002
Appl. No.:
10/228835
Inventors:
Barry Sherman - Hillsborough CA, US
Mary Remien - San Francisco CA, US
Remi Barbier - San Francisco CA, US
Kathleen Dumas - Cupertino CA, US
Grant Schoenhard - San Carlos CA, US
Mary Remien - San Francisco CA, US
Remi Barbier - San Francisco CA, US
Kathleen Dumas - Cupertino CA, US
Grant Schoenhard - San Carlos CA, US
International Classification:
A61K031/485
US Classification:
514/282000
Abstract:
The invention generally relates to novel compositions and methods with an opioid agonist and an opioid antagonist to differentially dose a human subject so as to either enhance analgesic potency without attenuating an adverse side effect of the agonist, or alternatively maintain the analgesic potency of the agonist while attenuating an adverse side effect of the agonist. The invention additionally relates to novel opioid compositions and methods for the gender-based dosing of men and women.
Opioid Antagonist Compositions And Dosage Forms
US Patent:
2003019, Oct 9, 2003
Filed:
Apr 9, 2002
Appl. No.:
10/119615
Inventors:
Barry Sherman - Hillsborough CA, US
Mary Remien - San Francisco CA, US
Remi Barbier - San Francisco CA, US
James McGinity - Austin TX, US
Mary Remien - San Francisco CA, US
Remi Barbier - San Francisco CA, US
James McGinity - Austin TX, US
International Classification:
A61K031/485
US Classification:
514/282000
Abstract:
The present invention is directed to novel dosage forms, pharmaceutical compositions, kits, and methods of administration of an opioid antagonist in an amount of at least about 0.0001 mg to about or less than about 1.0 mg, including from about 0.0001 mg to less than about 0.5 mg. Solid oral dosage forms are disclosed consisting essentially of an opioid antagonist or alternatively comprising an opioid antagonist and another active ingredient, such as an opioid agonist. Immediate release oral dosage forms are disclosed that release all or a substantial percentage of opioid antagonist, and another active ingredient when present, in a desired time. Concurrent release dosage forms are disclosed that provide concurrent release of an opioid antagonist and another active ingredient.
Treatment Of Cancer
US Patent:
8143447, Mar 27, 2012
Filed:
Sep 5, 2007
Appl. No.:
11/850626
Inventors:
Jerome Moore - Issaquah WA, US
Bruce Keyt - Hillsborough CA, US
John Burnier - Pacifica CA, US
Barry M. Sherman - Hillsborough CA, US
Max Totrov - San Diego CA, US
Valeria S. Ossovskaya - San Francisco CA, US
Bruce Keyt - Hillsborough CA, US
John Burnier - Pacifica CA, US
Barry M. Sherman - Hillsborough CA, US
Max Totrov - San Diego CA, US
Valeria S. Ossovskaya - San Francisco CA, US
Assignee:
BiPar Sciences, Inc. - South San Francisco CA
International Classification:
C07C 233/65, C07C 323/42, C07C 323/62
US Classification:
564162, 562431
Abstract:
The present invention provides compositions of matter, kits and methods for their use in the treatment of cancer. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase, as well as providing formulations and modes of administering such compositions.
Treatment Of Cancer
US Patent:
2012023, Sep 20, 2012
Filed:
Dec 12, 2011
Appl. No.:
13/323630
Inventors:
Jerome MOORE - Issaquah WA, US
Bruce KEYT - Hillsborough CA, US
John BURNIER - Pacifica CA, US
Barry SHERMAN - Hillsborough CA, US
Max TOTROV - San Diego CA, US
Valeria S. OSSOVSKAYA - San Francisco CA, US
Bruce KEYT - Hillsborough CA, US
John BURNIER - Pacifica CA, US
Barry SHERMAN - Hillsborough CA, US
Max TOTROV - San Diego CA, US
Valeria S. OSSOVSKAYA - San Francisco CA, US
Assignee:
BiPar Sciences, Inc. - Bridgewater NJ
International Classification:
A61K 31/166, A61K 31/472, A61K 31/426, A61P 35/00, A61K 31/421, A61K 31/381, A61K 31/404, A61K 31/197, A61K 31/4245
US Classification:
514309, 514562, 514618, 514365, 514364, 514374, 514438, 514415
Abstract:
The present invention provides compositions of matter, kits and methods for their use in the treatment of cancer. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase, as well as providing formulations and modes of administering such compositions.